Promising Growth Prospects for Scholar Rock: Buy Rating Backed by Apitegromab’s Potential and Strategic Milestones

Analyst Dennis Kennedy of LifeSci Capital maintained a Buy rating on Scholar Rock Holding (SRRK – Research Report), reducing the price target to $48.00.

Dennis Kennedy has given his Buy rating due to a combination of factors, primarily focusing on the promising potential of Scholar Rock’s lead product candidate, apitegromab. The company is poised for significant milestones, including the anticipated topline data from the Phase 2 EMBRAZE study in June 2025, which evaluates apitegromab in combination with Eli Lilly’s dual agonist for obesity treatment. This data could provide important insights into the drug’s efficacy and market potential.
Furthermore, Scholar Rock is on the verge of a pivotal moment with the expected FDA approval of apitegromab for spinal muscular atrophy (SMA) by September 2025. The company is strategically prepared for a commercial launch in the US and EU, with a well-equipped market access team and a comprehensive plan to support sales and patient services. These developments, coupled with a solid financial position, contribute to Kennedy’s confidence in the company’s growth prospects and justify the Buy rating.